NovaBay Pharmaceuticals Reports First Quarter Financial Results and Clinical and Business Update
May 02, 2013 08:15 ET
|
NovaBay Pharmaceuticals, Inc.
Clinical Results From Three Aganocide® Trials Expected in Second Half of 2013
EMERYVILLE, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a...
NovaBay Global Ophthalmology Study Enrolls First Patients in Brazil
April 08, 2013 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
BAYnovation Phase 2b Trial for the Treatment of Viral Conjunctivitis Spans Three Continents
EMERYVILLE, Calif., April 8, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE...
NovaBay CEO Interviewed on RedChip Money Report on Fox Business News
March 18, 2013 06:00 ET
|
NovaBay Pharmaceuticals, Inc.
- Dr. Ron Najafi Highlights Aganocide Anti-Infective Platform -
- NovaBay's First-In-Class Compounds Offer a New Treatment Paradigm to Address the Growing Crisis of Antibiotic Resistance...
NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results and 2013 Clinical and Business Update
March 14, 2013 06:14 ET
|
NovaBay Pharmaceuticals, Inc.
Well Positioned in 2013 with Three Phase 2b Clinical Trials for Conjunctivitis, Impetigo and UCBE Advancing
EMERYVILLE, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc....
NovaBay Pharmaceuticals to Present at the 25th Annual ROTH Conference
March 12, 2013 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing a large unmet therapeutic needs of the global...
NovaBay Names Keith Bley as Senior Vice President of Product Development
March 11, 2013 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Behzad Khosrovi Retires After Ten-Year Career at NovaBay
EMERYVILLE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused...
NovaBay Receives Unique Globally Recognized International Nonproprietary Name Auriclosene for NVC-422
February 20, 2013 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
-Data from Three Phase 2 Trials of Lead Aganocide Compound Anticipated in 2013 -
- Phase 3 Registration Trials Expected in 2014 -
EMERYVILLE, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) --...
NovaBay Partner Galderma Expands Phase 2b Trial Enrollment to South Africa
February 05, 2013 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Global Impetigo Study to Enroll Patients in Four Countries
EMERYVILLE, Calif., Feb. 5, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused...
NovaBay Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference
January 31, 2013 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 31, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals Announces Smartphone Investor App
January 15, 2013 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
App Provides Immediate Access to Company News and Financial Information
EMERYVILLE, Calif., Jan. 15, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology...